BOJHT
CRSP icon

Bank of Jackson Hole Trust’s CRISPR Therapeutics CRSP Stock Holding History

Bank of Jackson Hole Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$9.51K – 101
2026
Q1 		$9.51K Hold
200
– – ﹤0.01% 399
2025
Q4 		$10.5K Hold
200
– – 0.01% 388
2025
Q3 		$13K Hold
200
– – 0.01% 359
2025
Q2 		$9.73K Hold
200
– – 0.01% 374
2025
Q1 		$8.78K Hold
200
– – 0.01% 385
2024
Q4 		$7.87K Buy
+200
New +$9.44K 0.01% 392

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank of Jackson Hole Trust's CRSP Position: Q2 2026 in Review

Bank of Jackson Hole Trust sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 200 shares — an estimated $9.51K sold.

Bank of Jackson Hole Trust first reported a position in CRSP in Q4 2024 and held it in 6 quarters. The position peaked at $13K in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Bank of Jackson Hole Trust reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bank of Jackson Hole Trust sold 200 CRISPR Therapeutics shares in Q2 2026, an estimated $9.51K.
  • Bank of Jackson Hole Trust first reported a position in CRISPR Therapeutics in Q4 2024 and held it in 6 quarters.
  • Bank of Jackson Hole Trust's CRISPR Therapeutics position peaked at $13K in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Bank of Jackson Hole Trust's 13F filing for Q2 2026.